{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T16:33:41Z","timestamp":1723480421493},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1038\/s41433-020-01325-9","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T17:03:02Z","timestamp":1606755782000},"page":"3445-3447","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Current perspectives on the use of eplerenone for chronic central serous chorioretinopathy"],"prefix":"10.1038","volume":"35","author":[{"given":"Yonghui","family":"Xia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Hua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,30]]},"reference":[{"key":"1325_CR1","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0140-6736(19)32981-2","volume":"395","author":"A Lotery","year":"2020","unstructured":"Lotery A, Sivaprasad S, O\u2019Connell A, Harris RA, Culliford L, Ellis L, et al. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomized, double-blind, placebo-controlled trial. Lancet. 2020;395:294\u2013303.","journal-title":"Lancet."},{"key":"1325_CR2","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1136\/bjophthalmol-2019-314047","volume":"104","author":"DS Petkovsek","year":"2020","unstructured":"Petkovsek DS, Cherfan DG, Conti FF, Hom GL, Ehlers JP, Babiuch AS, et al. Eplerenone for the treatment of chronic central serous chorioretinopathy: 3-year clinical experience. Br J Ophthalmol. 2020;104:182\u20137.","journal-title":"Br J Ophthalmol"},{"key":"1325_CR3","doi-asserted-by":"crossref","unstructured":"Fraenkel D, Suffo S, Langenbucher A, Seitz B, Din Abdin A. Eplerenone for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol. 2020; 1120672120952648. Online ahead of print.","DOI":"10.1177\/1120672120952648"},{"key":"1325_CR4","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/S0161-6420(02)01975-9","volume":"110","author":"R Haimovici","year":"2003","unstructured":"Haimovici R, Rumelt S, Melby J. Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology. 2003;110:698\u2013703.","journal-title":"Ophthalmology."},{"key":"1325_CR5","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1172\/JCI61427","volume":"122","author":"M Zhao","year":"2012","unstructured":"Zhao M, C\u00e9l\u00e9rier I, Bousquet E, Jeanny JC, Jonet L, Savoldelli M, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Investig. 2012;122:2672\u20139.","journal-title":"J Clin Investig"},{"key":"1325_CR6","doi-asserted-by":"publisher","first-page":"100770","DOI":"10.1016\/j.preteyeres.2019.07.003","volume":"73","author":"TJ Van Rijssen","year":"2019","unstructured":"Van Rijssen TJ, van Dijk EHC, Yzer S, Ohno-Matsui K, Keunen JEE, Schlingemann RO, et al. Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res. 2019;73:100770.","journal-title":"Prog Retin Eye Res"},{"key":"1325_CR7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41433-018-0158-4","volume":"33","author":"CMG Cheung","year":"2019","unstructured":"Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB. Pachychoroid disease. Eye. 2019;33:14\u201333.","journal-title":"Eye"},{"key":"1325_CR8","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1002\/lsm.22952","volume":"50","author":"JY Min","year":"2018","unstructured":"Min JY, Lv Y, Yu S, Gong YY. Findings of OCT-angiography compared to fluorescein and indocyanine green angiography in central serous chorioretinopathy. Lasers Surg Med. 2018;50:987\u201393.","journal-title":"Lasers Surg Med"},{"key":"1325_CR9","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s00417-019-04297-z","volume":"257","author":"F Sulzbacher","year":"2019","unstructured":"Sulzbacher F, Sch\u00fctze C, Burgm\u00fcller M, V\u00e9csei-Marlovits PV, Weingessel B. Clinical evaluation of neovascular and non-neovascular chronic central serous chorioretinopathy (CSC) diagnosed by swept source optical coherence tomography angiography (SS OCTA). Graefes Arch Clin Exp Ophthalmol. 2019;257:1581\u201390.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1325_CR10","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1038\/s41433-020-0802-7","volume":"34","author":"SR Sadda","year":"2020","unstructured":"Sadda SR. Lack of efficacy of eplerenone for treatment of active central serous chorioretinopathy. Eye. 2020;34:1489\u201390.","journal-title":"Eye"},{"key":"1325_CR11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.pdpdt.2014.07.005","volume":"11","author":"R Hua","year":"2014","unstructured":"Hua R, Liu L, Li C, Chen L. Evaluation of the effects of photodynamic therapy on chronic central serous chorioretinopathy based on the mean choroidal thickness and the lumen area of abnormal choroidal vessels. Photodiagnosis Photodyn Ther. 2014;11:519\u201325.","journal-title":"Photodiagnosis Photodyn Ther."}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-020-01325-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-020-01325-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-020-01325-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:10:11Z","timestamp":1684617011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-020-01325-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,30]]},"references-count":11,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1325"],"URL":"https:\/\/doi.org\/10.1038\/s41433-020-01325-9","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,30]]},"assertion":[{"value":"13 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}